Skip to main content
. 2022 Feb 10;298(3):101709. doi: 10.1016/j.jbc.2022.101709

Figure 7.

Figure 7

Mfsd2a deficiency leads to reductions in total BAL phospholipids (PLs). Lipidomic analysis of AT2aKO and 2afl/fl BAL 4 weeks post-tamoxifen treatment. A, BAL lipid species represented as a volcano plot. Dots above dashed horizontal line indicate lipid species that are significantly different between AT2aKO and 2afl/fl AT2. Most of the lyso-PL and PL species are reduced in AT2aKO BAL relative to 2afl/fl control (PL, SL, and NL). Total PC 32:0 (B) and PL species containing DHA (PL-DHA) (C) or AA (PL-AA) (D) were reduced in AT2aKO BAL relative to 2afl/fl. BAL PLs (E) and lyso-PLs (F) represented as a heatmap. Color bar indicates z-score transformation on μmol/μl BAL PLs. Data for B–D are represented as mean μmol/μl BAL ± SE, with individual points denoting biological replicates. Fatty acid identity is designated as the number of carbons:number of double bonds. For all panels in this figure, 2afl/fl, n = 6; AT2aKO, n = 5. Unpaired t test with Welch's correction, ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. AA, arachidonic acid; AT2, alveolar epithelial type 2; BAL, bronchioalveolar lavage; DHA, docosahexaenoic acid; Mfsd2a, major facilitator superfamily domain containing 2a; NL, neutral lipid; PC, phosphatidylcholine; SL, sphingolipid.